A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People
A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.
Sponsor: Novo Nordisk A/S
Listed as NCT06336005, this PHASE1 trial focuses on Cardiometabolic Diseases and Healthy Volunteers and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 7 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2024 — Apr 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .